FCGR2A/CD32A and FCGR3A/CD16A variants and EULAR response to tumor necrosis factor-α blockers in psoriatic arthritis: A longitudinal study with 6 months of followup

  1. Ramírez, J.
  2. Fernández-Sueiro, J.L.
  3. López-Mejías, R.
  4. Montilla, C.
  5. Arias, M.
  6. Moll, C.
  7. Alsina, M.
  8. Sanmarti, R.
  9. Lozano, F.
  10. Cañete, J.D.
Journal:
Journal of Rheumatology

ISSN: 0315-162X 1499-2752

Year of publication: 2012

Volume: 39

Issue: 5

Pages: 1035-1041

Type: Article

DOI: 10.3899/JRHEUM.110980 GOOGLE SCHOLAR